Posted on July 16th, 2012 by
Alzheimer's researchers are cautiously hopeful that three new drugs undergoing clinical trials will slow the course of the mind-robbing disease… Neurologist Dr. Howard Feldman of the University of British Columbia in Vancouver said he'd interpret the Gammagard results very cautiously because they may not be statistically significant. "We may not have the right drug, we may not have the right timing, but we're on the right pathway," Feldman said. If not, Dr. Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center in Rochester, Minn., worries what could happen to the field. "If these studies are all flat, dead negative, then I think we're in trouble, the field is in trouble because I think a lot of other companies are going to bail on this notion," Pederson said.
Additional coverage: Yahoo! News Canada
Tags: alzheimer's disease, Alzheimer's Disease Research Center, CBC News, Dr. Howard Feldman, Dr. Ronald Petersen, Gammagard, Mayo Clinic Rochester, Neurology, Research, University of British Columbia
You must be logged-in to the site to post a comment.